LENZ Therapeutics (LENZ) Other Accumulated Expenses (2020 - 2023)

LENZ Therapeutics (LENZ) has reported Other Accumulated Expenses for 4 consecutive years, with $143000.0 the latest figure, recorded in Q4 2023.

• In Q4 2023, Other Accumulated Expenses fell 89.44% year-over-year to $143000.0; the TTM figure through Dec 2023 stood at $143000.0 (down 89.44% YoY), while the FY2023 annual figure was $143000.0, down 89.44% from the prior year.
• Other Accumulated Expenses slipped to $143000.0 in Q4 2023 per LENZ's latest filing, from $221000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $4.9 million in Q1 2023 and bottomed at $71000.0 in Q4 2020.
• Historically, Other Accumulated Expenses has averaged $1.0 million across 4 years, with a median of $420500.0 in 2021.
• On a YoY basis, Other Accumulated Expenses climbed as much as 1611.17% in 2023 and fell as far as 89.44% in 2023.
• LENZ Therapeutics' Other Accumulated Expenses stood at $71000.0 in 2020, then jumped by 411.27% to $363000.0 in 2021, then surged by 273.0% to $1.4 million in 2022, then slumped by 89.44% to $143000.0 in 2023.
• Business Quant data shows LENZ's Other Accumulated Expenses at $143000.0 in Q4 2023, $221000.0 in Q3 2023, and $3.1 million in Q2 2023.